Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis

BACKGROUNDSpontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical out...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of gastroenterology & hepatology 2016-07, Vol.28 (7), p.777-785
Hauptverfasser: Salman, Tary A, Edrees, Ahmed M, El-Said, Hala H, El-Abd, Osama L, El-Azab, Gasser I
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 785
container_issue 7
container_start_page 777
container_title European journal of gastroenterology & hepatology
container_volume 28
creator Salman, Tary A
Edrees, Ahmed M
El-Said, Hala H
El-Abd, Osama L
El-Azab, Gasser I
description BACKGROUNDSpontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. METHODSTwo hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. RESULTSSBP resolved in most of patients in all groups (P>0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. CONCLUSIONTerlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.
doi_str_mv 10.1097/MEG.0000000000000635
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1793908433</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1793908433</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3565-bd84c315e938c6bf92aad2743a2ff97bba5b4919bfa3f49e27359a383c2a18ac3</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi1URJeWN0DIxx6aEsdOHB9RtS1IRVxA6i2aOGPF4MTBdrTad-Ih6-0WhHqoL2Npvv-f0fyEvGflFSuV_Ph1e3tV_v8aXr8iGyYkL-qmlSdkU6paFI1i96fkbYw_y5JJzuQbclrJ7MBrsSF_tsagTtQbOtj8DTgnmkYMsOCarKaTH8DZZDFSP9O4jwknqy9pBsFdUpgHOuICB3TEDO9nyP342IijD6lIGCbq16T9lE3sTLUNYfQHxUGXB0a6s2mkcfFzghn9GmkPOussOLrkkvycV4jn5LUBF_HdUz0jP262368_F3ffbr9cf7orNK-buuiHVmjOalS81U1vVAUwVFJwqIxRsu-h7oViqjfAjVBY5VMo4C3XFbAWND8jF0ffJfjfK8bUTTZqdO64XMek4qpsBecZFUdUBx9jQNMtwU4Q9h0ru0NOXc6pe55Tln14mrD2Ew7_RH-DyUB7BHbe5UPEX27dYehGBJfGl70fAGanpIM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1793908433</pqid></control><display><type>article</type><title>Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>Salman, Tary A ; Edrees, Ahmed M ; El-Said, Hala H ; El-Abd, Osama L ; El-Azab, Gasser I</creator><creatorcontrib>Salman, Tary A ; Edrees, Ahmed M ; El-Said, Hala H ; El-Abd, Osama L ; El-Azab, Gasser I</creatorcontrib><description>BACKGROUNDSpontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. METHODSTwo hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. RESULTSSBP resolved in most of patients in all groups (P&gt;0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. CONCLUSIONTerlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.</description><identifier>ISSN: 0954-691X</identifier><identifier>EISSN: 1473-5687</identifier><identifier>DOI: 10.1097/MEG.0000000000000635</identifier><identifier>PMID: 27097354</identifier><language>eng</language><publisher>England: Copyright Wolters Kluwer Health, Inc. All rights reserved</publisher><subject>Adult ; Bacterial Infections - complications ; Bacterial Infections - physiopathology ; Drug Therapy, Combination ; Female ; Hemodynamics - drug effects ; Hepatorenal Syndrome - etiology ; Hepatorenal Syndrome - prevention &amp; control ; Humans ; Liver Circulation - drug effects ; Liver Cirrhosis - complications ; Liver Cirrhosis - physiopathology ; Lypressin - analogs &amp; derivatives ; Lypressin - therapeutic use ; Male ; Middle Aged ; Midodrine - therapeutic use ; Peritonitis - complications ; Peritonitis - physiopathology ; Renal Circulation - drug effects ; Serum Albumin - therapeutic use ; Treatment Outcome ; Vasoconstrictor Agents - therapeutic use</subject><ispartof>European journal of gastroenterology &amp; hepatology, 2016-07, Vol.28 (7), p.777-785</ispartof><rights>Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3565-bd84c315e938c6bf92aad2743a2ff97bba5b4919bfa3f49e27359a383c2a18ac3</citedby><cites>FETCH-LOGICAL-c3565-bd84c315e938c6bf92aad2743a2ff97bba5b4919bfa3f49e27359a383c2a18ac3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27097354$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Salman, Tary A</creatorcontrib><creatorcontrib>Edrees, Ahmed M</creatorcontrib><creatorcontrib>El-Said, Hala H</creatorcontrib><creatorcontrib>El-Abd, Osama L</creatorcontrib><creatorcontrib>El-Azab, Gasser I</creatorcontrib><title>Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis</title><title>European journal of gastroenterology &amp; hepatology</title><addtitle>Eur J Gastroenterol Hepatol</addtitle><description>BACKGROUNDSpontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. METHODSTwo hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. RESULTSSBP resolved in most of patients in all groups (P&gt;0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. CONCLUSIONTerlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.</description><subject>Adult</subject><subject>Bacterial Infections - complications</subject><subject>Bacterial Infections - physiopathology</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Hemodynamics - drug effects</subject><subject>Hepatorenal Syndrome - etiology</subject><subject>Hepatorenal Syndrome - prevention &amp; control</subject><subject>Humans</subject><subject>Liver Circulation - drug effects</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - physiopathology</subject><subject>Lypressin - analogs &amp; derivatives</subject><subject>Lypressin - therapeutic use</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Midodrine - therapeutic use</subject><subject>Peritonitis - complications</subject><subject>Peritonitis - physiopathology</subject><subject>Renal Circulation - drug effects</subject><subject>Serum Albumin - therapeutic use</subject><subject>Treatment Outcome</subject><subject>Vasoconstrictor Agents - therapeutic use</subject><issn>0954-691X</issn><issn>1473-5687</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcFu1DAQhi1URJeWN0DIxx6aEsdOHB9RtS1IRVxA6i2aOGPF4MTBdrTad-Ih6-0WhHqoL2Npvv-f0fyEvGflFSuV_Ph1e3tV_v8aXr8iGyYkL-qmlSdkU6paFI1i96fkbYw_y5JJzuQbclrJ7MBrsSF_tsagTtQbOtj8DTgnmkYMsOCarKaTH8DZZDFSP9O4jwknqy9pBsFdUpgHOuICB3TEDO9nyP342IijD6lIGCbq16T9lE3sTLUNYfQHxUGXB0a6s2mkcfFzghn9GmkPOussOLrkkvycV4jn5LUBF_HdUz0jP262368_F3ffbr9cf7orNK-buuiHVmjOalS81U1vVAUwVFJwqIxRsu-h7oViqjfAjVBY5VMo4C3XFbAWND8jF0ffJfjfK8bUTTZqdO64XMek4qpsBecZFUdUBx9jQNMtwU4Q9h0ru0NOXc6pe55Tln14mrD2Ew7_RH-DyUB7BHbe5UPEX27dYehGBJfGl70fAGanpIM</recordid><startdate>20160701</startdate><enddate>20160701</enddate><creator>Salman, Tary A</creator><creator>Edrees, Ahmed M</creator><creator>El-Said, Hala H</creator><creator>El-Abd, Osama L</creator><creator>El-Azab, Gasser I</creator><general>Copyright Wolters Kluwer Health, Inc. All rights reserved</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20160701</creationdate><title>Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis</title><author>Salman, Tary A ; Edrees, Ahmed M ; El-Said, Hala H ; El-Abd, Osama L ; El-Azab, Gasser I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3565-bd84c315e938c6bf92aad2743a2ff97bba5b4919bfa3f49e27359a383c2a18ac3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Bacterial Infections - complications</topic><topic>Bacterial Infections - physiopathology</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Hemodynamics - drug effects</topic><topic>Hepatorenal Syndrome - etiology</topic><topic>Hepatorenal Syndrome - prevention &amp; control</topic><topic>Humans</topic><topic>Liver Circulation - drug effects</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - physiopathology</topic><topic>Lypressin - analogs &amp; derivatives</topic><topic>Lypressin - therapeutic use</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Midodrine - therapeutic use</topic><topic>Peritonitis - complications</topic><topic>Peritonitis - physiopathology</topic><topic>Renal Circulation - drug effects</topic><topic>Serum Albumin - therapeutic use</topic><topic>Treatment Outcome</topic><topic>Vasoconstrictor Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Salman, Tary A</creatorcontrib><creatorcontrib>Edrees, Ahmed M</creatorcontrib><creatorcontrib>El-Said, Hala H</creatorcontrib><creatorcontrib>El-Abd, Osama L</creatorcontrib><creatorcontrib>El-Azab, Gasser I</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European journal of gastroenterology &amp; hepatology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Salman, Tary A</au><au>Edrees, Ahmed M</au><au>El-Said, Hala H</au><au>El-Abd, Osama L</au><au>El-Azab, Gasser I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis</atitle><jtitle>European journal of gastroenterology &amp; hepatology</jtitle><addtitle>Eur J Gastroenterol Hepatol</addtitle><date>2016-07-01</date><risdate>2016</risdate><volume>28</volume><issue>7</issue><spage>777</spage><epage>785</epage><pages>777-785</pages><issn>0954-691X</issn><eissn>1473-5687</eissn><abstract>BACKGROUNDSpontaneous bacterial peritonitis (SBP) is a major risk factor for hepatorenal syndrome. Albumin infusion has been shown to prevent renal impairment and reduce mortality in SBP. The study aimed to compare the effect of different therapeutic modalities on hemodynamics and short clinical outcomes in high-risk patients with SBP. METHODSTwo hundred cirrhotic patients with SBP and bilirubin greater than 4 mg[Fraction Slash]dl or creatinine more than 1 mg[Fraction Slash]dl were enrolled. Patients were randomized to receive albumin, terlipressin, low-dose albumin plus terlipressin, or midodrine. Systemic, renal, and hepatic hemodynamics were estimated at baseline, 3, and 10 days of treatment. Renal impairment was diagnosed when the blood urea nitrogen or serum creatinine levels increased by more than 50% of the pretreatment value. RESULTSSBP resolved in most of patients in all groups (P&gt;0.05). Cardiac output and portal flow decreased, whereas systemic vascular resistance increased significantly in terlipressin and albumin plus terlipressin groups compared with the albumin group after 3 and 10 days. After 10 days, plasma renin activity, renal, and hepatic arteries resistive index were significantly higher in the midodrine group compared with the albumin group. The midodrine group did not show any significant changes in the heart rate, mean arterial pressure, cardiac output, and portal blood flow compared with the albumin group after 3 or 10 days. There was no significant difference in renal impairment or mortality between any of the groups. CONCLUSIONTerlipressin and low-dose albumin plus terlipressin could be used as a therapeutic alternative to standard-dose albumin in high-risk SBP patients.</abstract><cop>England</cop><pub>Copyright Wolters Kluwer Health, Inc. All rights reserved</pub><pmid>27097354</pmid><doi>10.1097/MEG.0000000000000635</doi><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0954-691X
ispartof European journal of gastroenterology & hepatology, 2016-07, Vol.28 (7), p.777-785
issn 0954-691X
1473-5687
language eng
recordid cdi_proquest_miscellaneous_1793908433
source MEDLINE; Journals@Ovid Complete
subjects Adult
Bacterial Infections - complications
Bacterial Infections - physiopathology
Drug Therapy, Combination
Female
Hemodynamics - drug effects
Hepatorenal Syndrome - etiology
Hepatorenal Syndrome - prevention & control
Humans
Liver Circulation - drug effects
Liver Cirrhosis - complications
Liver Cirrhosis - physiopathology
Lypressin - analogs & derivatives
Lypressin - therapeutic use
Male
Middle Aged
Midodrine - therapeutic use
Peritonitis - complications
Peritonitis - physiopathology
Renal Circulation - drug effects
Serum Albumin - therapeutic use
Treatment Outcome
Vasoconstrictor Agents - therapeutic use
title Effect of different therapeutic modalities on systemic, renal, and hepatic hemodynamics and short-term outcomes in cirrhotic patients with spontaneous bacterial peritonitis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T06%3A41%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20different%20therapeutic%20modalities%20on%20systemic,%20renal,%20and%20hepatic%20hemodynamics%20and%20short-term%20outcomes%20in%20cirrhotic%20patients%20with%20spontaneous%20bacterial%20peritonitis&rft.jtitle=European%20journal%20of%20gastroenterology%20&%20hepatology&rft.au=Salman,%20Tary%20A&rft.date=2016-07-01&rft.volume=28&rft.issue=7&rft.spage=777&rft.epage=785&rft.pages=777-785&rft.issn=0954-691X&rft.eissn=1473-5687&rft_id=info:doi/10.1097/MEG.0000000000000635&rft_dat=%3Cproquest_cross%3E1793908433%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1793908433&rft_id=info:pmid/27097354&rfr_iscdi=true